Acoziborole

SCYX-7158.svg

Acoziborole is an investigational antiparasitic drug being developed for the treatment of human African trypanosomiasis (HAT), also known as sleeping sickness. This disease is caused by the protozoan parasites Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, which are transmitted to humans by the bite of an infected tsetse fly.

Mechanism of Action

Acoziborole works by inhibiting the enzyme Trypanosoma brucei adenosine kinase, which is essential for the parasite's survival. By blocking this enzyme, acoziborole disrupts the parasite's ability to synthesize adenosine triphosphate (ATP), leading to its death.

Clinical Development

Acoziborole is currently in clinical trials and has shown promise in early studies. It is being developed as an oral treatment, which would be a significant improvement over existing therapies that require intravenous administration. The drug has the potential to simplify the treatment regimen for HAT, making it more accessible to patients in remote areas.

Efficacy and Safety

In clinical trials, acoziborole has demonstrated efficacy in clearing the parasite from the bloodstream and central nervous system. The safety profile of the drug is also being closely monitored, with initial results indicating that it is well-tolerated by patients.

Significance

The development of acoziborole represents a significant advancement in the fight against neglected tropical diseases. If approved, it could provide a much-needed treatment option for patients suffering from HAT, particularly in sub-Saharan Africa where the disease is most prevalent.

See Also

• Human African trypanosomiasis
• Trypanosoma brucei
• Neglected tropical diseases
• Antiparasitic drugs